AIM: To evaluate the safety of compacted DNA nanoparticles (NPs) in retinal pigment epithelial (RPE) cells. MATERIALS & METHODS: Enhanced GFP expression cassettes controlled by the RPE-specific vitelloform macular dystrophy promoter were constructed with and without a bacterial backbone and compacted into NPs formulated with polyethylene glycol-substituted lysine 30-mers. Single or double subretinal injections were administered in adult BALB/c mice. Expression levels of enhanced GFP, proinflammatory cytokines and neutrophil/macrophage mediators, and retinal function by electroretinogram were evaluated at different time-points postinjection. RESULTS: Immunohistochemistry and real-time PCR demonstrated that NPs specifically transfect RPE cells at a higher efficiency than naked DNA and similar results were observed after the second injection. At 6 h postinjections, a transient inflammatory response was observed in all cohorts, including saline, indicating an adverse effect to the injection procedure. Subsequently, no inflammation was detected in all experimental groups. CONCLUSION: This study demonstrates the safety and efficacy of NP-mediated RPE gene transfer therapy following multiple subretinal administrations.
AIM: To evaluate the safety of compacted DNA nanoparticles (NPs) in retinal pigment epithelial (RPE) cells. MATERIALS & METHODS: Enhanced GFP expression cassettes controlled by the RPE-specific vitelloform macular dystrophy promoter were constructed with and without a bacterial backbone and compacted into NPs formulated with polyethylene glycol-substitutedlysine 30-mers. Single or double subretinal injections were administered in adult BALB/c mice. Expression levels of enhanced GFP, proinflammatory cytokines and neutrophil/macrophage mediators, and retinal function by electroretinogram were evaluated at different time-points postinjection. RESULTS: Immunohistochemistry and real-time PCR demonstrated that NPs specifically transfect RPE cells at a higher efficiency than naked DNA and similar results were observed after the second injection. At 6 h postinjections, a transient inflammatory response was observed in all cohorts, including saline, indicating an adverse effect to the injection procedure. Subsequently, no inflammation was detected in all experimental groups. CONCLUSION: This study demonstrates the safety and efficacy of NP-mediated RPE gene transfer therapy following multiple subretinal administrations.
Authors: T L Fink; P J Klepcyk; S M Oette; C R Gedeon; S L Hyatt; T H Kowalczyk; R C Moen; M J Cooper Journal: Gene Ther Date: 2006-03-09 Impact factor: 5.250
Authors: Assem-Galal Ziady; Christopher R Gedeon; Timothy Miller; William Quan; Jennifer M Payne; Susannah L Hyatt; Tamara L Fink; Osman Muhammad; Sharon Oette; Tomasz Kowalczyk; Murali K Pasumarthy; Robert C Moen; Mark J Cooper; Pamela B Davis Journal: Mol Ther Date: 2003-12 Impact factor: 11.454
Authors: Assem-Galal Ziady; Christopher R Gedeon; Osman Muhammad; Virginia Stillwell; Sharon M Oette; Tamara L Fink; Will Quan; Tomasz H Kowalczyk; Susannah L Hyatt; Jennifer Payne; Angela Peischl; J E Seng; Robert C Moen; Mark J Cooper; Pamela B Davis Journal: Mol Ther Date: 2003-12 Impact factor: 11.454
Authors: May Nour; Alexander B Quiambao; Ward M Peterson; Muayyad R Al-Ubaidi; Muna I Naash Journal: Invest Ophthalmol Vis Sci Date: 2003-10 Impact factor: 4.799
Authors: David M Yurek; Anita M Fletcher; George M Smith; Kim B Seroogy; Assem G Ziady; Joseph Molter; Tomasz H Kowalczyk; Linas Padegimas; Mark J Cooper Journal: Mol Ther Date: 2009-02-17 Impact factor: 11.454
Authors: Malgorzata Przybylska; I-Huan Wu; Hongmei Zhao; Robin J Ziegler; Jennifer D Tousignant; Robert J Desnick; Ronald K Scheule; Seng H Cheng; Nelson S Yew Journal: J Gene Med Date: 2004-01 Impact factor: 4.565
Authors: Susie E Barker; Cathryn A Broderick; Scott J Robbie; Yanai Duran; Mythili Natkunarajah; Prateek Buch; Kamaljit S Balaggan; Robert E MacLaren; James W B Bainbridge; Alexander J Smith; Robin R Ali Journal: J Gene Med Date: 2009-06 Impact factor: 4.565